British Business Bank Commits £21 Million to EQT Life Sciences to Back UK Medtech Scaleups

The British Business Bank has committed €25 million, roughly £21 million, to EQT Life Sciences' Health Economics 3 fund, adding a dedicated pool of growth capital for medtech, diagnostics and digital health companies at a stage of the funding journey that UK founders in this sector consistently describe as the hardest to close.

The commitment targets commercial stage, de-risked medtech and digital health businesses, the point at which a company has proven its technology works but still needs serious capital to scale manufacturing, distribution or clinical adoption before it can credibly raise from public markets or attract acquirers. That stage has been a persistent gap in UK life sciences funding: early stage grant and angel money is comparatively plentiful, and later stage private equity will write large cheques once revenue is established, but the growth capital that bridges the two has been thin, pushing some of the UK's most promising medtech companies to look overseas for the capital needed to scale.

The British Business Bank's involvement is not a one-off. It builds on an existing relationship with EQT Life Sciences, having previously co-invested alongside the firm in Phagenesis' $42 million Series D round and Cyted Health's $44 million Series B, both UK headquartered companies. That pattern matters for founders assessing which investors are genuinely committed to the sector rather than opportunistically dipping in: a state-owned development bank returning to the same manager across multiple portfolio companies signals a considered, repeatable strategy rather than a single speculative bet.

For founders, the practical significance is straightforward. A dedicated growth-stage medtech fund, backed by a British Business Bank commitment, is more likely to understand the specific regulatory, reimbursement and clinical adoption timelines that make medtech and diagnostics companies different from software businesses to underwrite, and less likely to force founders into a generalist growth equity template that does not fit how healthcare technology actually scales and sells. The commitment also signals to other institutional investors, including UK pension funds that have been criticised for allocating minimal capital to private markets, that this stage of life sciences funding carries a credible, de-risking cornerstone investor.

The commitment is part of the British Business Bank's wider Industrial Strategy remit, which names life sciences as one of eight priority growth sectors. That framing matters less for the amount of capital involved than for what it says about sequencing: rather than treating medtech scale-up funding as a market failure to be fixed later, it is being addressed as a named, current priority alongside the earlier-stage diversity and emerging manager commitments the Bank has made this year.

Key Takeaways

• The British Business Bank has committed €25 million (about £21 million) to EQT Life Sciences' Health Economics 3 fund.

• The fund targets commercial-stage, de-risked medtech, diagnostics and digital health companies, a growth-capital gap UK founders in the sector have long flagged as the hardest stage to fund.

• The commitment builds on an existing relationship, following co-investments in Phagenesis' $42 million Series D and Cyted Health's $44 million Series B.

• For founders, a specialist manager with British Business Bank backing offers underwriting that better fits medtech's regulatory and clinical adoption timelines than generalist growth equity.

• Life sciences is one of eight priority sectors in the UK's Industrial Strategy, and the commitment signals continued, rather than one-off, state-backed investment in this stage of the market.

Sources: Tech.eu (British Business Bank Backs EQT Life Sciences with €25M Commitment), British Business Bank press materials